» Articles » PMID: 27412076

Antagonizing Retinoic Acid Receptors Increases Myeloid Cell Production by Cultured Human Hematopoietic Stem Cells

Overview
Publisher Sciendo
Date 2016 Jul 15
PMID 27412076
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Activities of the retinoic acid receptor (RAR)α and RARγ are important to hematopoiesis. Here, we have investigated the effects of receptor selective agonists and antagonists on the primitive human hematopoietic cell lines KG1 and NB-4 and purified normal human hematopoietic stem cells (HSCs). Agonizing RARα (by AGN195183) was effective in driving neutrophil differentiation of NB-4 cells and this agonist synergized with a low amount (10 nM) of 1α,25-dihydroxyvitamin D to drive monocyte differentiation of NB-4 and KG1 cells. Treatment of cultures of human HSCs (supplemented with stem cell factor ± interleukin 3) with an antagonist of all RARs (AGN194310) or of RARα (AGN196996) prolonged the lifespan of cultures, up to 55 days, and increased the production of neutrophils and monocytes. Slowing down of cell differentiation was not observed, and instead, hematopoietic stem and progenitor cells had expanded in number. Antagonism of RARγ (by AGN205728) did not affect cultures of HSCs. Studies of CV-1 and LNCaP cells transfected with RAR expression vectors and a reporter vector revealed that RARγ and RARβ are activated by sub-nM all-trans retinoic acid (EC-0.3 nM): ~50-fold more is required for activation of RARα (EC-16 nM). These findings further support the notion that the balance of expression and activity of RARα and RARγ are important to hematopoietic stem and progenitor cell expansion and differentiation.

Citing Articles

Targeting Androgen, Thyroid Hormone, and Vitamin A and D Receptors to Treat Prostate Cancer.

Hantusch B, Kenner L, Stanulovic V, Hoogenkamp M, Brown G Int J Mol Sci. 2024; 25(17).

PMID: 39273194 PMC: 11394715. DOI: 10.3390/ijms25179245.


Molecular Interactions of Selective Agonists and Antagonists with the Retinoic Acid Receptor γ.

Powala K, Zolek T, Brown G, Kutner A Int J Mol Sci. 2024; 25(12).

PMID: 38928275 PMC: 11203493. DOI: 10.3390/ijms25126568.


International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023.

Burris T, de Vera I, Cote I, Flaveny C, Wanninayake U, Chatterjee A Pharmacol Rev. 2023; 75(6):1233-1318.

PMID: 37586884 PMC: 10595025. DOI: 10.1124/pharmrev.121.000436.


Deregulation of All- Retinoic Acid Signaling and Development in Cancer.

Brown G Int J Mol Sci. 2023; 24(15).

PMID: 37569466 PMC: 10419198. DOI: 10.3390/ijms241512089.


The Promise of Retinoids in the Treatment of Cancer: Neither Burnt Out Nor Fading Away.

Nagai Y, Ambinder A Cancers (Basel). 2023; 15(14).

PMID: 37509198 PMC: 10377082. DOI: 10.3390/cancers15143535.


References
1.
Metcalf D, Burgess A . Clonal analysis of progenitor cell commitment of granulocyte or macrophage production. J Cell Physiol. 1982; 111(3):275-83. DOI: 10.1002/jcp.1041110308. View

2.
Teng M, Duong T, Klein E, PINO M, Chandraratna R . Identification of a retinoic acid receptor alpha subtype specific agonist. J Med Chem. 1996; 39(16):3035-8. DOI: 10.1021/jm9603532. View

3.
Allegretto E, McClurg M, Lazarchik S, Clemm D, Kerner S, Elgort M . Transactivation properties of retinoic acid and retinoid X receptors in mammalian cells and yeast. Correlation with hormone binding and effects of metabolism. J Biol Chem. 1993; 268(35):26625-33. View

4.
Tzezana R, Reznik S, Blumenthal J, Zussman E, Levenberg S . Regulation of stem cell differentiation by control of retinoic acid gradients in hydrospun 3D scaffold. Macromol Biosci. 2012; 12(5):598-607. DOI: 10.1002/mabi.201100312. View

5.
HEYMAN R, Mangelsdorf D, Dyck J, Stein R, Eichele G, Evans R . 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell. 1992; 68(2):397-406. DOI: 10.1016/0092-8674(92)90479-v. View